Company Filing History:
Years Active: 2010-2024
Title: Konstantin Ichtchenko: Innovator in Neurotoxin Research
Introduction
Konstantin Ichtchenko is a notable inventor based in Brooklyn, NY. He has made significant contributions to the field of neurotoxin research, holding a total of 6 patents. His work focuses on innovative therapeutic agents and treatment methods that utilize Clostridial neurotoxins.
Latest Patents
One of his latest patents is titled "Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain." This invention is directed to a fusion protein that includes a light chain region and a heavy chain region of a Clostridial neurotoxin, linked by a disulfide bond. The fusion protein also features a single chain antibody positioned upstream of the light chain region, which possesses antigen-binding activity. Additionally, the patent discloses therapeutic agents, treatment methods, propeptide fusions, isolated nucleic acid molecules, expression systems, host cells, and methods of expressing fusion proteins. Another significant patent is related to "treatment methods using atoxic neurotoxin derivatives." This method involves treating a subject with an isolated, physiologically active, atoxic derivative of a Clostridial neurotoxin, which does not possess a cargo attachment peptide sequence at its N-terminus.
Career Highlights
Konstantin Ichtchenko is affiliated with New York University, where he continues to advance his research in neurotoxin applications. His innovative work has garnered attention in the scientific community, contributing to the understanding and potential therapeutic uses of neurotoxins.
Collaborations
Some of his notable coworkers include Philip A Band and Edwin J Vazquez-Cintron. Their collaborative efforts have further enhanced the research and development of neurotoxin-related therapies.
Conclusion
Konstantin Ichtchenko's contributions to neurotoxin research exemplify the impact of innovative thinking in the field of medicine. His patents and ongoing work continue to pave the way for new therapeutic approaches.